Active Surveillance Program to Increase Awareness on Invasive Fungal Diseases: the French RESSIF Network (2012 to 2018)
- Type de publi. : Article dans une revue
- Date de publi. : 28/06/2022
-
Auteurs :
Stéphane BretagneKarine SitbonM. Desnos-OllivierDea Garcia-HermosoValérie BruSophie CassaingLaurence MillonFlorent MorioJean-Pierre GangneuxLilia HasseineLoïc FavennecEstelle CateauEric BaillyMaxime MoniotJulie BonhommeNicole Desbois-NogardTaieb ChouakiAndré PaugamBernard BouteilleMarc PihetFrédéric DalleOdile EloyMilène SassoMagalie DemarPatricia Mariani-KurkdjianVincent RobertOlivier LortholaryFrançoise DromerThe French Mycoses Study GroupCéline DamianiHervé DupontJulien MaizelAnne TotetJean-Philippe BoucharaAnne Pauline BellangerAna BerceanuJean Christophe NavellouEmeline SchererPhilippe AbboudChristine AznarDenis BlanchetFélix DjossouSophie CayotCyril GarrousteOlivier LesensCécile MoluçonCéline NourrissonPhilippe PoirierÉloïse BaillyLouise BasmaciyanBouhemad BelaidMathieu BlotDenis CaillotPierre-Emmanuel CharlesJean-Pierre QuenotEmmanuelle AmazanEmilie BaubionAndré CabieCyrille ChabartierChristophe DelignyViolaine EmalOlivier FlechelleYves HatchuelYohann Le GovicHarold MerleCharline MiossecJean-Marie TurmelRuddy ValentinoMarie-Fleur DurieuxPascal TurlureVictor MercierMartine Gari-ToussaintKarine RissoLoïc SimonCedric BretonnièreDavid BoutoilleThomas GastinneKarim LakhalElise LaunayThierry LepoivrePierre PeterlinFanny RiallandPatrice Le PapeEtienne CanouiNaima DahaneSolène KerneisCécile AngebaultMarie-Elisabethh BougnouxNadia GuennouniFanny LanternierBennedicte NevenMehdi OualhaAnne ScemlaEmilie SitterléFelipe SuarezJulie ToubianaStéphane BonacorciAlexandre AlanioAnne BergeronBlandine DenisMaud Gits-MuselliSamia HamaneSophie TouratierChristine ChaumeilLilia MerabetJoelle ClaudéonElodie CurlierValérie GalantineJean Claude GalloisSamuel MarkowiczMuriel NicolasPascal MussonKinda SchepersAlida MinozaCatherine Kauffmann-LacroixHélène GuéganDamien CostaMarion DehaisGilles GargalaOdile BajoletFirouze BanisadrJoel CoussonChantal HimberlinAntoine HugueninDominique ToubasPierre FloriCaroline MahincHélène RaberinJulie DenisRaoul HerbrechtPaul-Michel MertesFehrat MezianiAlina-Marcela SabouFrancis SchneiderAnne-Isabelle BertozziPamela ChauvinEléna CharpentierOlivier CointaultClaire CottrelKaren DelavigneStanislas FaguerJudith FillauxEmilie GuemasXavier IriartLucie LelièvreJean RuizFrédéric BastidesAdélaïde ChesnayGuillaume DesoubeauxAudrey TherbyElisabeth ChachatyBertrand Gachot
-
Organismes :
Mycologie moléculaire - Molecular Mycology
Hopital Saint-Louis [AP-HP]
Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals
Mycologie moléculaire - Molecular Mycology
Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals
Mycologie moléculaire - Molecular Mycology
Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals
Mycologie moléculaire - Molecular Mycology
Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals
Dynamique des interactions hôte pathogène
Centre Hospitalier Universitaire de Toulouse
Geroscience and rejuvenation research center
Laboratoire Chrono-environnement (UMR 6249)
Cibles et Médicaments des Infections et de l'Immunité - UR 1155
Institut de recherche en santé, environnement et travail
Centre Hospitalier Universitaire de Nice
CHU Rouen
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
Écologie et biologie des interactions [UMR 7267]
Centre Hospitalier Régional Universitaire de Tours
CHU Clermont-Ferrand
CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie
Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique]
CHU Amiens-Picardie
Hôpital Cochin [AP-HP]
CHU Limoges
SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques
Laboratoire de Parasitologie-Mycologie (CHU d'Angers)
Infections Respiratoires Fongiques
Procédés Alimentaires et Microbiologiques [Dijon]
Centre Hospitalier de Versailles André Mignot
Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle
Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]
Hôpital Robert Debré Paris
Westerdijk Fungal Biodiversity Institute [Utrecht]
Mycologie moléculaire - Molecular Mycology
Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals
Service des Maladies infectieuses et tropicales [CHU Necker]
Mycologie moléculaire - Molecular Mycology
Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals
Agents infectieux, résistance et chimiothérapie - UR UPJV 4294
Simplification des soins chez les patients complexes - UR UPJV 7518
Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517
Agents infectieux, résistance et chimiothérapie - UR UPJV 4294
Infections Respiratoires Fongiques
SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques
Laboratoire de Parasitologie-Mycologie [CHU Angers]
Agents infectieux, résistance et chimiothérapie - UR UPJV 4294
Pathogenesis and Control of Chronic and Emerging Infections
Hôpital Bretonneau
Centre d’Etude des Pathologies Respiratoires [Tours]
- Publié dans mBio le 21/10/2020
Résumé : The French National Reference Center for Invasive Mycoses and Antifungals leads an active and sustained nationwide surveillance program on probable and proven invasive fungal diseases (IFDs) to determine their epidemiology in France. Between 2012 and 2018, a total of 10,886 IFDs were recorded. The incidence increased slightly over time (2.16 to 2.36/10,000 hospitalization days, P = 0.0562) in relation with an increase of fungemia incidence (1.03 to 1.19/10,000, P = 0.0023), while that of other IFDs remained stable. The proportion of ≥65-year-old patients increased from 38.4% to 45.3% (P < 0.0001). Yeast fungemia (n = 5,444) was due mainly to Candida albicans (55.6%) with stable proportions of species over time. Echinocandins became the main drug prescribed (46.7% to 61.8%), but global mortality rate remained unchanged (36.3% at 1 month). Pneumocystis jirovecii pneumonia (n = 2,106) was diagnosed mostly in HIV-negative patients (80.7%) with a significantly higher mortality than in HIV-positive patients (21.9% versus 5.4% at 1 month, P < 0.0001). Invasive aspergillosis (n = 1,661) and mucormycosis (n = 314) were diagnosed mostly in hematology (>60% of the cases) with a global mortality rate of 42.5% and 59.3%, respectively, at 3 months and significant changes in diagnosis procedure over time. More concurrent infections were also diagnosed over time (from 5.4% to 9.4% for mold IFDs, P = 0.0115). In conclusion, we observed an aging of patients with IFD with a significant increase in incidence only for yeast fungemia, a trend toward more concurrent infections, which raises diagnostic and therapeutic issues. Overall, global survival associated with IFDs has not improved despite updated guidelines and new diagnostic tools. IMPORTANCE The epidemiology of invasive fungal diseases (IFDs) is hard to delineate given the difficulties in ascertaining the diagnosis that is often based on the confrontation of clinical and microbiological criteria. The present report underlines the interest of active surveillance involving mycologists and clinicians to describe the global incidence and that of the main IFDs. Globally, although the incidence of Pneumocystis pneumonia, invasive aspergillosis, and mucormycosis remained stable over the study period (2012 to 2018), that of yeast fungemia increased slightly. We also show here that IFDs seem to affect older people more frequently. The most worrisome observation is the lack of improvement in the global survival rate associated with IFDs despite the increasing use of more sensitive diagnostic tools, the availability of new antifungal drugs very active in clinical trials, and a still low/marginal rate of acquired in vitro resistance in France. Therefore, other tracks of improvement should be investigated actively.
Fichiers liés :
mbio.00920-22.pdf
Source